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Background: CpGmethylation in the O6-methylguanine-DNAmethyltransferase (MGMT) promoter is associated
with better outcome following alkylating agent chemotherapy in glioblastoma (GBM) and anaplastic glioma
(AG). To what extent improved response reﬂects low or absent MGMT activity in glioma tissue has not been
unequivocally assessed. This information is central to developing anti-resistance therapies.
Methods:Weexamined the relationship ofMGMT activity in 91 GBMs and 84 AGs with progression-free survival
(PFS) following alkylator therapy andwith promotermethylation status determined bymethylation-speciﬁc PCR
(MSP).
Results: Cox regression analysis revealed that GBMs with high activity had a signiﬁcantly greater risk for
progression indichotomous (P≤ 0.001) and continuous (P≤ 0.003)models, an association observed for different
alkylator regimens, including concurrent chemo-radiation with temozolomide. Analysis of MGMT promoter
methylation status in 47 of the GBMs revealed that methylated tumors had signiﬁcantly lower activity
(P ≤ 0.005) and longer PFS (P ≤ 0.036) compared to unmethylated tumors, despite overlapping activities. PFS
was also signiﬁcantly greater in methylated vs. unmethylated GBMs with comparable activity (P ≤ 0.005),
and among unmethylated tumors with less than median activity (P ≤ 0.026), suggesting that mechanisms in
addition to MGMT promote alkylator resistance. Similar associations of MGMT activity with PFS and promoter
methylation status were observed for AGs.
Conclusions: Our results provide strong support for the hypotheses that MGMT activity promotes alkylator
resistance and reﬂects promoter methylation status in malignant gliomas.
General signiﬁcance:MGMT activity is an attractive target for anti-resistance therapy regardless of methylation
status.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND 4.0 license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Glioblastoma (GBM;WHOgrade 4) is among themost lethal human
cancers with approximately 13,000 individuals newly diagnosed in the
U.S. annually [1]. Therapy has long included surgery to the safest extent2-chloroethyl)-1-nitrosourea;
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anine-DNAmethyltransferase;
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.
. This is an open access article underpossible followed by involved-ﬁeld radiotherapy (RT). Chemotherapy
with nitrosourea-based methylating and/or chloroethylating agents
given after RThas done little to improve clinical outcome [2]. In contrast,
inclusion of the triazene methylator temozolomide (TMZ) concurrently
with RT, and continued as a single agent after completing RT (chemo-
RT) adds an average of 12 weeks overall survival in newly diagnosed
GBMs, and as a result is now the contemporary standard of care [2,3].
Nevertheless, the majority of GBMs are not responsive to chemo-RT,
and tumors that initially respond inevitably become refractory. Conse-
quently, the prognosis for GBM remains dismal with most patients
dyingwithin 9 to 15months [3]. Chemo-RT is also used in the treatment
of anaplastic (i.e., WHO grade 3) gliomas (AGs), a heterogeneous group
of gliomas that are histologically, genetically and clinically distinct from
GBM [4]. AGs generally show greater responsiveness to adjuvant RTthe CC BY-NC-ND 4.0 license (http://creativecommons.org/licenses/by/4.0/).
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at least in part, to genetic alterations not found in GBMs. As a conse-
quence most AGs have a better prognosis and longer overall survival
than GBMs [4–8]. While chemo-RT is increasingly used in the adjuvant
therapy of AGs, its efﬁcacy compared to the contemporary standard of
care of ﬁrst line RT or alkylators awaits demonstration in ongoing
clinical trials [4].
Extensive preclinical data demonstrate that the DNA repair protein
O6-methylguanine-DNA methyltransferase (MGMT) limits the efﬁcacy
of TMZ and other clinical alkylators [9,10]. MGMT is the sole human
activity that excises O6-methylguanine (O6-meG) [11], a minority
(~5–7%), cytotoxic base adduct produced by TMZ andothermethylators
[12]. MGMT covalently transfers the methyl group to an internal
cysteine residue, yielding an inactive S-alkylcysteine-modiﬁed protein
and guanine [11]. This “suicide”mechanism constrains the number of
O6-meG adducts that can be removed from DNA in vivo to the number
of MGMT molecules in cells and the rate of re-synthesis of the protein.
MGMT also excises O6-chloroethylguanine, the progenitor of cytotoxic
inter-strand crosslinks [9,11].
MGMT activity varies widely (~300-fold) in GBMs and other
gliomas, with a minority lacking biochemically detectable activity [9,
13]. Absence of MGMT activity in GBM-derived cell lines and xenografts
is associated with hypermethylation of CpG dinucleotides in theMGMT
promoter region [3,9], indicating that expression can be epigenetically
silenced. Hypermethylation of the MGMT promoter has also been
observed in an appreciable fraction of GBMs and other gliomas [3].
Importantly, numerous studies have shown that MGMT promoter
methylation is associated with longer survival in newly diagnosed
GBMs following chemo-RT [3]. Prolonged survival has also been
observed in GBMs, and in lower-grade gliomas treated with adjuvant
alkylating agents following completion of RT [3,14–16]. These observa-
tions provide evidence that promoter methylation accompanies a
treatment-sensitive phenotype and has utility as a prognostic and, in
some instances, as a predictive marker [15,17].
The association of promoter methylation status with clinical
response strongly suggests that absence or low expression of MGMT
promotes alkylator sensitivity in vivo. This hypothesis has been exam-
ined primarily by immunohistochemistry (IHC) to determine the
fraction of MGMT-expressing GBM cells in sections of formalin-ﬁxed
parafﬁn embedded tissue [reviewed in 17,18]. However, low MGMT
expression has not consistently accompanied better treatment response
in GBMs with MGMT promoter methylation [13,19]. The disparity
among these studies has been attributed to a variety of limitations,
including lack of standardized scoring criteria and small sample size
[discussed in 18]. MGMT biochemical activity provides a direct and
objective means of quantifying MGMT expression in human tumors.
However, MGMT activity has also not consistently shown an association
with either clinical response to alkylating agents [13,20,21] or promoter
methylation status [22,23]. The discordance between these studies
likely reﬂects, in part, the limited number of samples analyzed in
some cases, differences in reporting MGMT activity (e.g., normalization
to cell protein vs. cell number) and, in some instances, the inclusion of
both GBMs and AGs in analyses.
Herewe analyzed the association ofMGMT biochemical activity [24]
with progression-free survival (PFS) following alkylator-based chemo-
therapy in the largest cohort of GBMs and anaplastic gliomas (AGs)
reported to date. Univariate Cox regression models, with activity
entered either as a dichotomous variable using median activity as the
cut point or as a continuous variable, revealed an inverse association
between MGMT activity and PFS in 91 GBMs and in 84 AGs. The associ-
ation was observed in tumor sub-groups segregated by demographic,
clinical and genetic markers associated with treatment response. In all
groups examined, less than median MGMT activity was associated
with longer PFS following alkylators therapy. Signiﬁcantly, lower
MGMT activity and longer PFS following alkylator therapy were each
associated with promoter methylation [determined by methylation-speciﬁc PCR (MSP)] in the 47 GBMs and 34 AGs that were examined.
Additional ﬁndings not previously reported are that PFS for methylated
tumors was signiﬁcantly greater than that for unmethylated tumors
with comparable activity, and that among unmethylated GBMs, lower
than median MGMT activity was associated with signiﬁcantly lower
risk for progression following alkylator therapy. Overall, our data
strongly indicate that MGMT activity mediates resistance to alkylator
therapy and that low MGMT activity is responsible, at least in part,
for the better response that accompanies promoter methylation. Our
data also suggest that suppression of MGMT activity may promote
better response to alkylators regardless of promotermethylation status.2. Materials and methods
2.1. Tissue and treatment outcome
One hundred forty-two GBMs and 133 AGs were obtained with
informed consent from adult patients operated at the University of
Washington Medical Center between 1991 and 2012. Diagnoses were
in accord with WHO criteria [5] and reﬂected the consensus of a panel
of neuropathologists. GBMs harboring mutant IDH1/2 or with histolog-
ical evidence of progression from a lower grade glioma (so-called
secondary GBM) were excluded from this study. Course of treatment
and radiologic documentation of progression was reviewed by the
multidisciplinary UW Neuro-Oncology Tumor Board comprised of
physicians providing patient care. Tumor, treatment and demographic
information were obtained in accordance with protocols approved by
the Institutional Review Board at the University of Washington. Care
was taken to ensure that tumor tissue samples obtained for MGMT
activity were adjacent to tumor submitted for pathology and were
distant from the margins of normal brain. Multiple single-use aliquots
of tumorswere snap frozen immediately after excision and subsequent-
ly stored under liquid nitrogen. In our experience, tumors stored in this
fashion retain enzymatic activity and DNA integrity for more than 20
years.2.2. Radiation and alkylating agent-based chemotherapy
All 275 tumors received standard, conformal RT (~60 Gy in 30
fractions over 6 weeks). Ninety-one GBMs (64% of all GBMs) and 84
AGs (63% of all AGs) also received alkylating agent-based chemothera-
py. The total number of GBM and AG patients receiving each alkylator
regimen is described below: the number of individual GBMs and AGs
treated is entered in Tables 1 and 4, respectively. Fifty-six patients
were given daily TMZ (75 mg/m2) during RT followed by adjuvant
TMZ (200 mg/m2) daily for the ﬁrst 5 days of a 28 day cycle for
as many as 6 cycles for GBM (EORTC 26981; [25]) and as many as 19
cycles for AG. Six tumors received a single dose of BCNU (200 mg/m2)
immediately prior to the ﬁrst fraction of RT followed by up to 6 cycles
of adjuvant BCNU (200 mg/m2) every 6 to 8 weeks after completing
RT. The remaining gliomas completed RT prior to receiving one of the
following alkylating agent regimens: TMZ (200 mg/m2) daily for the
ﬁrst 5 days of a 28 day cycle, the cycle repeated until tumor progression;
procarbazine, CCNU and vincristine (PCV), given as described [26]; PCV
plus 6-thioguanine, dibromodulcitol, 5-ﬂuorouracil and hydroxyurea
using the doses and schedules previously described [27]; single agent
BCNU (200 mg/m2) every 6 to 8 weeks for up to 6 cycles; BCNU
(80 mg/m2) with cisplatin (33 mg/m2) daily for 3 days every 6 weeks
for 3 cycles followed by BCNU (80 mg/m2) daily for 3 days every 6
weeks for 2 cycles. Chemotherapy was terminated upon radiologic
evidence of tumor progression (see below). All patients had a Karnofsky
performance score ≥70 at time of operation. Approximately 60% of
GBMs and 80% of AGs that recurred after alkylator-based chemotherapy
received additional surgery, RT and/or chemotherapy.
Table 1
GBMMGMT activity and PFS following alkylator therapy.





Mean ± SD; [median];
(range)
All alkylator-treated GBM 91 82 (90%) 6 9.4 ± 11; [5.8]; (b0.25–57)
Exclude outlier MGMT
activitiesb
81 73 (90%) 6.5 6.4 ± 4.9; [5]; (b0.25–22)
Exclude upper and
lower 10% of PFS
73 67 (92%) 6 9.9 ± 11; [5.6]; (0.25–57)
Prior treatment
None and biopsy onlyc 69 63 (91%) 6.5 9.4 ± 11; [5.4]; (b0.25–57)
Surgery or biopsy followed
by RTd
22 19 (86%) 5 9.5 ± 9.8; [5.9]; (1.2–39)
Age
Younger (b50) 41 37 (90%) 6 9.4 ± 11; [5.7]; (0.8–57)
Older (≥50) 50 45 (90%) 6 9.6 ± 10; [6.3]; (b0.25–43)
Progression after RTe
No 50 44 (88%) 8 8.6 ± 11; [5]; (0.7–57)
Yesf 41 38 (93%) 4.5 11 ± 11; [6.3]; (b0.25–40)
Alkylator therapy
Chemo-RT 33 28 (85%) 7.5 9.9 ± 12; [5.4]; (0.7–57)
RT then alkylatorsa 58 54 (93%) 5 9.2 ± 9.8; [5.8]; (b0.25–40)
None (i.e., RT only) 51 50 (98%) 3 8.6 ± 8.9; [6.1]; (b0.25–40)
a Includes 22 tumors treated with TMZ, 20 treated with PCV-based chemotherapy and
16 treated with BCNU.
b Limiting activities to those within the 95% conﬁdence interval for the data eliminated
the 10 highest MGMT activities.
c Includes 60 newly operated tumors and 9 that were previously biopsied; MGMT
activity is that obtained at debulking operation.
d MGMT activity determined in recurrent tumor re-operated after RT.
e Prior to initiating alkylator therapy.
f Includes 22 tumors re-operated for recurrence after surgery or biopsy and RT.
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MGMT activity in extracts of whole tissue was measured in a
standard biochemical assay that quantiﬁes the transfer of radioactivity
from a DNA substrate containing [methyl-3H]O6-methylguanine
(speciﬁc activity, 17–80 Ci/mmol) to protein, as we have previously
described [21,24]. Supernatants were prepared either by homogeniza-
tion followed by sonication of tissue in isotonic buffer [21], or by
extraction of powdered tissue with non-ionic detergents in the
presence of 600 mM NaCl [28]. In both instances, crude homogenates
were cleared by centrifugation at 10,000 ×g for 30 min. The insoluble
pellet was saved for DNA extraction for MSP analysis described below.
MGMT activity in supernatants prepared from the same tumor using
both extraction techniques differed by less than 3-fold in all cases, a
difference which did not affect the relationship between activity and
PFS (see below). DNA was quantiﬁed in crude homogenates by the
diphenylamine method that measures deoxyribose following degrada-
tion of DNA with heat and acid [29]. Activity was normalized to cell
number using a conversion factor of 6 pg DNA per human cell. All
activities are the mean of at least 4 determinations that generally
differed by no more than 20%, and MGMT-expressing specimens
displayed linearity of activity with added extract. Control experiments
validating assay speciﬁcity, the range of activities, and absence of
detectable activity as well as parameters deﬁning the limit of detection
of the assay (b0.25 fmol/106 cells or 151 molecules/cell) have been de-
scribed in detail [21,24]. Whenever possible, tumors were re-extracted
to conﬁrm absence of detectable activity.2.4. MGMT promoter methylation
The CpGmethylation status of theMGMT promoter was determined
by MSP of bisulﬁte-treated DNA [3,30]. Tumor DNA was isolated from
the insoluble material pelleted during non-ionic detergent tissue
extractions (above) by solubilization in SDS followed by serial salt andalcohol precipitation. Bisulﬁte treatment, PCR primers and reaction
conditions were essentially those described elsewhere [31]. Five μg of
genomic DNA was used for each MSP assay. For each sample, methyla-
tion status is the concordant results of at least two separate bisulﬁte
reactions and aminimumof two ampliﬁcation reactions for each aliquot
of bisulﬁte-treated DNA. DNA from MGMT-expressing (SF767) and
MGMT-deﬁcient (SNB19) human glioma cell lines [32] served as
controls. MGMT activity and CpG methylation were determined using
the same piece of tumor tissue.
2.5. Statistical analysis
The outcome variable PFS, i.e., the interval between the initiation of
alkylator treatment and tumor progression, was assessed by radiologic
imaging. Overall survival (OS) was the interval between initial surgery/
biopsy todate of death. Tumorprogressionwas deﬁned as the appearance
of new tumor growth in the case of gross total resection (i.e., excision of all
contrast enhancing tissue), or increase in the product of the orthogonal
diameters of residual tumor by at least 25% and/or tumor growth at a dif-
ferent site in the case of sub-total resection. Observations were censored
at the last documented follow-up time if progression had not occurred.
Median PFS was determined by the method of Kaplan and Meier and
compared using log-rank test. The hazard ratio (HR) for tumor progres-
sion as a function of MGMT activity was determined by Cox proportional
hazards regression analysis with activity entered as either a dichotomous
or a continuous variable. In the case of dichotomous analyses, themedian
MGMT activity of each group examined was used as the cut point.
Adjusting for extractionmethod had no effect on the association between
activity and PFS in either dichotomous or continuous models (data not
shown). For purposes of calculation, MGMT-non-expressing tumors
were assigned a value of 0.125 fmol/106 cells, one-half the limit of detec-
tion; using 0 or 0.25 fmol/106 cells did not alter the results of the analyses.
All analyses were performed using Stata software (Stata Corporation,
College Station, TX).
3. Results
3.1. GBM: tumor characteristics, treatment and MGMT activity
We assayed MGMT activity in 91 GBMs that were treated with
upfront RT and alkylating agents. Patients ranged in age from 21 to 79
years (mean ± SD = 52 ± 12); 59 tumors (65%) were from males
and 32 (35%) from females. Distribution of tumors by prior treatment,
age and response to RT prior to beginning alkylator treatment is
summarized in Table 1. Approximately equal numbers of GBMs were
from patients younger than 50 and those 50 and older. Sixty-nine
GBMs were either newly operated (N = 60) or had been biopsied
(N=9) prior to deﬁnitive surgical resection;MGMT activity was deter-
mined in the specimen obtained from surgical resection. Another 22
were re-operated following recurrence after previous surgery and
RT; MGMT activity was determined in the specimen obtained at re-
operation. Adjuvant alkylator treatment began immediately after
completing RT in 50 tumors, and commenced only after tumor progres-
sion in the remaining 41 GBMs. Thirty-three GBMs received chemo-RT
while the remaining 58 tumors completed RT prior to treatment with
TMZ (N = 22), PCV (N = 20) or BCNU (N = 16). Eighty-two tumors
(90%) had documented progression after alkylator therapy and 9 were
lost to follow up. Median progression-free survival (PFS) was 6months.
As shown in Table 1, mean MGMT activity for the 91 alkylator-
treated GBMs was 9.4 ± 11 fmol/106 cells (i.e., ~5700 ± 6650
molecules/cell). Activity ranged more than 225-fold from b0.25 to 57
fmol/106 cells. Table 1 also shows that activity was not affected by
recurrence after previous surgery and RT, age, or withholding alkylator
therapy until recurrence after RT, results consistent with our previously
reported ﬁndings [21,24]. MGMT activity was also assayed in 51 newly
operated GBMs that were subsequently treated with RT alone: Patient
4 M.S. Bobola et al. / BBA Clinical 3 (2015) 1–10age (52 ± 12 years) and fraction of treatment failures in the RT only
population were comparable to that of the alkylator-treated GBMs.
3.2. MGMT activity is inversely associated with alkylating agent response in
GBM
The inverse association between MGMT activity and response to
alkylator treatment in 91 GBMs is illustrated in Fig. 1 that compares
survival, estimated by the Kaplan–Meier method, for tumors with
less than or greater than median activity (5.8 fmol/106 cells, i.e., ~3500
MGMT molecules/cell). As shown in Table 2, GBMs with greater than
median MGMT activity had an approximately 2.4-fold higher hazard
ratio (HR) for progression which was accompanied by signiﬁcantly
shorter median PFS (4 vs. 7.5 months; P ≤ 0.0001; Fig. 1; Table 3)
following alkylating agent therapy. EnteringMGMT activity as a contin-
uous variable also revealed a signiﬁcant inverse relationship and a
≥5.0-fold (i.e., 1.029(57–0.25)) difference in risk of progression between
tumors with the lowest and highest MGMT.
Further analysis indicated that the inverse association did not reﬂect
the presence of a small number of tumorswith outlierMGMT activity or
PFS. Limiting the analysis to the 81 tumors within the 95% conﬁdence
interval for MGMT activities (Table 1) revealed a statistically signiﬁcant
relationship in both dichotomous and continuous models (Table 2).
Signiﬁcant relationships also persisted when tumors with the highest
and lowest 10% of PFS were excluded (Table 2). Prior treatment with
RT also had no effect on the association. Restricting the analysis to
the 69 newly operated or previously biopsied GBMs (median activity
5.4 fmol/106 cells, i.e., ~3250 MGMT molecules/cell) produced HR
comparable to that observed for all 91 tumors in both dichotomous
and continuous regression models (Table 2), and revealed a ≥6.3-fold
(i.e., 1.033(57–0.25)) increase in risk of progression between the lowest
and highestMGMT activity. These observations indicate that the associ-
ation between MGMT and PFS is not biased by the shorter PFS of 22
GBMs in our sample that were re-operated at recurrence following RT
(5 vs. 6.5 months; P≤ 0.035; Table 1). Altogether, these results indicate
that the correlation between MGMT and PFS is not determined by a
limited number of outliers and that MGMT activity in re-operated
tumors retains the association with PFS. These conclusions are support-
ed by the signiﬁcantly longer PFS that accompanied less than median
activity in each population (Table 3).
3.3. Association of MGMT with PFS is independent of age, clinical history or
alkylator therapy
Increasing age is a prognostic factor associated with worse clinical
outcome in GBM [1]. However, as shown in Table 2, the association
between MGMT and PFS was very similar in tumors from younger
(b50) and older (≥50) patients, suggesting that age did not signiﬁcantly
affect the correlation. That age does not inﬂuence the association wasFig. 1. Progression-free survival (PFS) for 91 glioblastomas (GBM) and 84 anaplastic gliomas (A
fmol/106 cells for GBMs; 4.1 fmol/106 cells for AGs), and survival curves were calculated by
signiﬁcantly shorter median PFS for GBM (4 vs. 7.5 months; P ≤ 0.0004) and for AGs (12 vs. 43further evidenced by the signiﬁcantly longer PFS observed for tumors
with less than median MGMT activity for both younger and older
patients (Table 3).
GBMs in our study did not all receive the same course of treatment
(Table 1). An appreciable fraction of tumors (41/91, 45%) recurred
after RT prior to starting alkylating agent-based chemotherapy, a factor
associated with signiﬁcantly reduced PFS (4.5 vs. 8 months; P ≤ 0.001;
Table 1). However, as shown in Table 2, intervening recurrence had no
effect on the association of MGMT with PFS in both dichotomous and
continuous regression models. Moreover, less than median MGMT
activity was associated with longer PFS (Table 3) further strengthening
the conclusion that recurrence after RT had no effect on the association
of MGMT activity with response. Similar results were observed for
GBMs treatedwith chemo-RT orwith alkylating agents after completing
RT (Tables 2 and 3). Importantly,MGMT activity showedno relationship
with PFS in GBMs treated solely with RT, and with overall survival in
GBMs treated with both RT and alkylators (Tables 2 and 3). Together,
the foregoing ﬁndings strongly indicate that MGMT is not merely a
marker for a broader resistance phenotype in GBM, but that the associ-
ation with outcome reﬂects a speciﬁc function of MGMT, namely exci-
sion of cytotoxic O6-alkylguanine adducts.
3.4. AG: tumor characteristics, treatment and MGMT activity
As alkylators are frequently a component of the adjuvant therapy
for AGs [4–8], we also analyzed the association betweenMGMT activity
and PFS in 84 AGs treatedwith upfront RT and alkylating agents. Patient
age was 42± 11 years (range 20 to 74) with 40 tumors frommales and
44 from females. The distribution of tumors by diagnosis, prior treat-
ment, response to RT, and prior diagnosis of low-grade (i.e., grade 2)
glioma is summarized in Table 4. The AGs included 35 anaplastic astro-
cytomas (AA), 24 anaplastic oligodendrogliomas (AO) and 25 anaplastic
mixed oligo-astrocytomas (AOA). Fifty-seven AGs were either newly
operated (N=46) or had been previously operated (N=7) or biopsied
(N = 4); MGMT activity was determined in the specimen obtained at
re-operation. Twenty-seven tumors were re-operated at recurrence
after previous surgery and RT; MGMT activity was determined in the
specimen obtained at re-operation. Of the 38 AGs re-operated at recur-
rence after surgery/biopsy alone or surgery followed by RT, 30 (79%)
had a diagnosis of low-grade (i.e., grade 2) glioma at ﬁrst surgery.
Alkylator treatment began immediately after completing RT in 45 tu-
mors, and commenced only after tumor progression in the remaining
39 AGs. Twenty-three tumors received TMZ concurrently during RT
followed by adjuvant TMZ, and the remaining 61 AGs completed RT be-
fore beginning treatment with PCV (N = 42), TMZ (N = 15), or BCNU
(N = 4). Sixty tumors (71%) had documented progression after
alkylator therapy, 12 have stable disease and 12 were lost to follow
up. Median progression-free survival for all AGs treated with alkylators
was 16 months, signiﬁcantly longer than the 6 months observed forG) according toMGMT activity. Tumors were dichotomized bymedianMGMT activity (5.8
the method of Kaplan–Meier. Greater than median MGMT activity was accompanied by
months; P ≤ 0.0003).
Table 2
Hazard ratio estimates for association between MGMT activity and PFS in GBMa.
Tumor sample Dichotomousb Continuous
N HR 95% CI P≤ HR 95% CI P≤
All alkylator-treated GBM 91 2.43 [1.535; 3.85] 0.001 1.029 [1.010; 1.048] 0.003
Exclude outlier MGMT activitiesc 81 2.02 [1.257; 3.26] 0.004 1.094 [1.036; 1.156] 0.001
Exclude upper and lower 10% of PFS 73 1.76 [1.072; 2.88] 0.025 1.026 [1.005; 1.046] 0.013
Prior treatment
None and biopsy onlyd 69 2.56 [1.501; 4.36] 0.001 1.033 [1.012; 1.054] 0.002
Surgery or biopsy followed by RTe 22 8.70 [2.31; 32.7] 0.001 1.024 [0.980; 1.071] 0.29
By age
Younger (b50 years) 41 2.07 [1.048; 4.10] 0.036 1.037 [1.007; 1.067] 0.015
Older (≥50 years) 50 2.77 [1.455; 5.30] 0.002 1.029 [1.002; 1.058] 0.037
Progression after RT
No 50 2.41 [1.258; 4.62] 0.008 1.035 [1.008; 1.063] 0.012
Yesf 41 4.60 [2.09; 9.97] 0.001 1.032 [1.003; 1.062] 0.030
Alkylator therapy
Chemo-RT 33 2.39 [1.048; 5.44] 0.038 1.032 [1.002; 1.062] 0.034
RT then alkylatorsg 58 2.41 [1.379; 4.21] 0.002 1.038 [1.010; 1.068] 0.009
None (i.e., RT only) 51 1.059 [0.603; 1.86] 0.84 1.022 [0.986; 1.060] 0.23
Overall survivalh 83 1.270 [0.805; 2.00] 0.30 1.002 [0.981; 1.023] 0.88
a The relationship between MGMT activity in GBMs and PFS following alkylating agent therapy was examined by using Cox proportional hazards regression analysis.
b Tumor activity was dichotomized at the median of each group examined.
c Limiting activities to those within the 95% conﬁdence interval for the data eliminated the 10 highest MGMT activities.
d Includes 60 newly operated tumors and 9 that were previously biopsied; MGMT activity is that obtained at debulking operation.
e MGMT activity assayed in recurrent tumor re-operated after RT.
f Includes the 22 tumors re-operated for recurrence after biopsy and RT.
g Includes 22 tumors treated with TMZ, 20 treated with PCV-based chemotherapy and 16 treated with BCNU.
h Date of ﬁrst operation was unavailable for 8 tumors that had recurred after prior surgery followed by RT.
Table 4
AGMGMT activity and PFS following alkylator therapy.
Tumor sample PFS post alkylator
therapy
MGMT (fmol/106 cells)
5M.S. Bobola et al. / BBA Clinical 3 (2015) 1–10GBM (P ≤ 0.001) and in accord with the better prognosis that accom-
panies AGs [4,5].
As summarized in Table 4, mean MGMT activity for all alkylator-
treated AGs was 5.9 ± 6.7 fmol/106 cells (i.e., ~3550 ± 4000 mole-
cules/cell) and ranged ~130-fold from b0.25 to mol/fmol/106 cells.
Mean activity was signiﬁcantly lower in AGs compared to GBMs
(9.4 ± 11 vs. 5.9 ± 6.7 fmol/106 cells; P≤ 0.01), in accord with our pre-
viously reported ﬁndings [21,24]. Table 4 also shows that activity was
not affected by recurrence after previous surgery and RT, withholdingTable 3
GBM PFS dichotomized by median MGMT activity.





All alkylator-treated GBM 91 7.5 4 0.0001
Exclude outlier MGMT activitiesb 81 7.5 5 0.003
Exclude upper and lower 10% of PFS 73 7 5 0.020
Prior treatment
None and biopsy onlyc 69 8.5 5 0.0003
Surgery or biopsy followed by RTd 22 6.5 4 0.0002
Age
Younger (b50) 41 8 4 0.030
Older (≥50) 50 7 4.5 0.0008
Progression after RT
No 50 9.5 6 0.005
Yese 41 5 2 0.0001
Alkylator therapy
Chemo-RT 33 8.5 6 0.030
RT then alkylatorsf 58 7 3 0.008
None (i.e., RT only) 51 3 3 0.83
Overall survivalg 73 17 14 0.30
a Determined by log rank test.
b Limiting activities to those within the 95% conﬁdence interval for the data eliminated
the 10 highest MGMT activities.
c Includes 60 newly operated tumors and 9 that were previously biopsied; MGMT
activity is that obtained at debulking operation.
d MGMT activity assayed in recurrent tumor re-operated after RT.
e Includes the 22 tumors re-operated for recurrence after biopsy and RT.
f Includes 22 tumors treated with TMZ, 20 treated with PCV-based chemotherapy and
16 treated with BCNU.
g Date of ﬁrst operation was unavailable for 8 tumors that had recurred after prior
surgery followed by radiotherapy.alkylator therapy until recurrence after RT, or prior diagnosis of low-
grade glioma. MGMT activity was also assayed in 49 AGs that were
treatedwith RT alone; patient age (42±13years), fraction of treatmentN Failures Median
(mo)
Mean ± SD; [median];
(range)
All alkylator-treated AG 84 60 (71%) 16 5.9 ± 6.7; [4.1]; (b0.25–32)
Exclude outlier MGMT
activitiesa
78 54 (69%) 21 4.4 ± 3.6; [3.6]; (b0.25–14)
Exclude upper and
lower 10% of PFS
68 51 (75%) 16 5.6 ± 6.6; [3.8]; (b0.25–32)
Without 1p and/or19q
deleted AO/AOA
71 54 (76%) 16 6.3 ± 7.1; [4.1]; (b0.25–32)
Diagnosis
Anaplastic astrocytoma 35 28 (80%) 15 6.2 ± 7.1; [3.2]; (b0.25–32)
Anaplastic
oligodendroglioma
24 17 (71%) 13 5.6 ± 6.4; [4.2]; (b0.25–32)
Anaplastic oligo-
astrocytoma
25 15 (60%) 24 5.8 ± 6.7; [3.8]; (b0.25–29)
Prior treatment
None and surgery or
biopsy onlyb
57 37 (65%) 16 5.8 ± 6.5; [4.1]; (b0.25–32)
Surgery or biopsy
followed by RTc
27 23 (85%) 19 6.2 ± 7.1; [4.1]; (b0.25–32)
Progression after RT
No 45 27 (60%) 26 4.7 ± 4.2; [3.8]; (b0.25–23)
Yesd 39 33 (85%) 16 7.3 ± 8.6; [4.3]; (b0.25–32)
Prior low-grade glioma
No 54 38 (70%) 14 6.7 ± 7.1; [4.8]; (b0.25–32)
Yes 30 22 (73%) 22 4.6 ± 5.8; [3.1]; (b0.25–29)
Alkylator therapy
PCV 42 42 (100%) 16 4.8 ± 5.9; [3.1]; (b0.25–32)
All other alkylatorse 42 28 (67%) 14 7.1 ± 7.3; [4.9]; (b0.25–32)
None (i.e., RT only) 49 30 (61%) 18 7.3 ± 8.9; [4.0]; (b0.25–49)
a Limiting activities to those within the 95% conﬁdence interval for the data eliminated
the 6 highest MGMT activities.
b Includes 11 tumors previously operated or biopsied.
c MGMT activity assayed in recurrent tumor re-operated after RT.
d Includes the 27 tumors re-operated for recurrence after surgery or biopsy and RT.
e Includes 23 tumors treated with chemo-RT, 15 with TMZ and 4 with BCNU.
Table 6
AG PFS dichotomized by median MGMT activity.
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All alkylator-treated AG 84 43 12 0.0003
Exclude outlier MGMT activitiesb 78 43 14 0.002
Exclude upper and lower 10% of PFS 68 22 13 0.025
Without 1p and/or 19q deleted AO/AOA 71 26 8 0.0001
Prior treatment
None and surgery or biopsy onlyc 57 48 12 0.004
Surgery or biopsy followed by RT 27 21 13 0.068
By diagnosis
Anaplastic astrocytoma 35 21 8 0.022
Anaplastic oligodendroglioma 24 47 12 0.009
Anaplastic oligo-astrocytoma 25 43 13 0.038
Prior treatment
None and surgery or biopsy onlyc 57 48 12 0.004
Surgery or biopsy followed by RT 27 21 13 0.068
Progression after RT
No 45 112 15 0.020
Yesd 39 22 7 0.0006
Prior low-grade glioma
No 54 47 8 0.006
Yes 30 24 19 0.044
Alkylator therapy
PCV 42 24 8 0.0001
Other than PCVe 42 26 13 0.055
None (i.e., RT only) 49 18 19 0.43
Overall survivalf 84 68 53 0.58
a Determined by log rank test.
b Limiting activities to those within the 95% conﬁdence interval for the data eliminated
the 6 highest MGMT activities.
c Includes seven previously operated and 4 previously biopsied tumors.
d Includes the 27 tumors re-operated for recurrence after surgery or biopsy and RT.
e Includes 23 tumors treated with chemo-RT, 15 with TMZ and 4 with BCNU.
f Date of initial surgery not available for one tumor.3.5. MGMT activity is inversely associated with alkylating agent response in
AG
The inverse relationship between MGMT activity and PFS following
alkylator therapy in 84 AGs is shown in Fig. 1 that compares survival,
estimated by the Kaplan–Meiermethod, for tumorswithMGMT activity
less than or greater than the median (4.1 fmol/106 cells, i.e., ~2500
molecules/cell). AGs with greater than median activity had a 2.6-fold
greater risk of progression (Table 5) and an ~3.5-fold shorter median
PFS after alkylating agent therapy (Fig. 1; Table 6). A signiﬁcant inverse
relationship was also observed when MGMT activity was entered as a
continuous variable (Table 5); the risk for progression differed by
~9.1-fold (1.072(32–0.25)) between the tumors with the lowest and
highest MGMT activity. Restricting analysis to the 78 AGs within the
95% conﬁdence interval for MGMT activities and the 68 tumors exclud-
ing the upper and lower 10% of PFS also yielded statistically signiﬁcant
associations (Table 5), indicating that the relationship was not deter-
mined by a limited number of outliers. Limiting analysis to the 57 AGs
that had received no RT prior to surgery (median activity = 4.1 fmol/
106 cells) in a dichotomous model, revealed that tumors with greater
than median MGMT activity had an elevated risk for progression
(Table 5). A continuousmodel also yielded a signiﬁcant inverse relation-
ship (Table 5) that showed a 41-fold (1.124(32–0.25)) difference in risk
for progression between the tumors with the lowest and highest
MGMT activity. Near signiﬁcant associations were also observed for
AGs that were re-operated at recurrence after surgery/biopsy followed
by RT (Table 5). These ﬁndings indicate that the correlation between
MGMT and PFS is not determined by a limited number of outliers and
that MGMT activity in re-operated tumors retains the association with
PFS. These conclusions are supported by the signiﬁcantly longer PFS
that accompanied less than median activity in each population
(Table 6).Table 5
Hazard ratio estimates for association between MGMT activity and PFS in AGsa.
Tumor sample Dichotomousb Continuous
N HR 95% CI P≤ HR 95% CI P≤
All alkylator-treated AG 84 2.57 [1.505; 4.39] 0.001 1.072 [1.039; 1.107] 0.001
Exclude outlier MGMTc 78 2.34 [1.343; 4.07] 0.003 1.109 [1.032; 1.192] 0.005
Exclude upper and lower 10% of PFS 68 1.88 [1.074; 3.28] 0.03 1.064 [1.025; 1.104] 0.01
Exclude 1p 19q deleted 71 2.94 [1.664; 5.19] 0.001 1.072 [1.038; 1.109] 0.001
Prior treatment
None and surgery or biopsy aloned 57 2.57 [1.309; 5.03] 0.006 1.124 [1.071; 1.180] 0.001
Surgery or biopsy followed by RT 27 2.26 [0.911; 5.63] 0.08 1.045 [0.933; 1.10] 0.09
By diagnosis
Anaplastic Astrocytoma 35 2.40 [1.102; 5.21] 0.027 1.050 [1.005; 1.097] 0.029
Anaplastic oligodendroglioma 24 3.58 [1.283; 9.92] 0.015 1.110 [1.027; 1.199] 0.008
Anaplastic oligo-astrocytoma 25 2.90 [1.010; 8.31] 0.048 1.130 [1.036; 1.234] 0.006
Progression after RT
No 45 2.50 [1.113; 5.62] 0.027 1.112 [1.027; 1.204] 0.009
Yese 39 3.51 [1.620; 7.61] 0.001 1.065 [1.027; 1.106] 0.001
Prior low-grade glioma
No 54 2.43 [1.252; 4.71] 0.009 1.061 [1.023; 1.100] 0.002
Yes 30 2.39 [1.000; 5.77] 0.054 1.127 [1.036; 1.225] 0.005
By alkylator treatment
PCV 42 3.72 [1.825; 7.58] 0.001 1.112 [1.051; 1.176] 0.001
All other alkylatorsf 42 2.07 [0.959; 4.85] 0.064 1.061 [1.019; 1.106] 0.004
None (i.e., RT only) 49 0.746 [0.357; 1.556] 0.43 0.985 [0.943; 1.029] 0.50
Overall survivalg 83 1.02 [0.614; 1.69] 0.94 1.028 [0.988; 1.070] 0.17
a The relationship between MGMT activity in AGs and PFS following alkylating agent therapy was examined by using Cox proportional hazards regression analysis.
b Tumor activity was dichotomized at the median of each diagnosis (Table 4).
c Limiting activities within the 95% conﬁdence interval for the data eliminated the 6 highest MGMT activities.
d Includes seven previously operated and 4 previously biopsied tumors.
e Includes the 27 tumors re-operated for recurrence after surgery or biopsy and RT.
f Includes 23 tumors treated with chemo-RT, 15 with TMZ and 4 with BCNU.
g Date of initial surgery not available for one tumor.
Fig. 2.MGMT activity and promoter methylation status in GBM and AG. MGMT activities
for 45 GBMs and 34 AGs are shown, together with the mean ± SD, for tumors displaying
either unmethylated or methylatedMGMT promoters, determined by MSP. Mean activity
was signiﬁcantly lower in methylated GBMs (4.4 ± 2.7 vs. 14 ± 11 fmol/106 cells; P ≤
0.001) and AGs (3.7 ± 2.7 vs. 11 ± 8.6 fmol/106 cells; P ≤ 0.0001).
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tory or alkylator therapy
As shown in Table 5, MGMT activity was inversely correlated with
PFS in both dichotomous and continuous regression models in each of
the three AG diagnoses. This observation suggests that the association
of outcomewithMGMT in all 84 AGs does not merely reﬂect the contri-
bution of treatment-responsive oligodendroglial tumors harboring
deletions on chromosomes 1p and 19q [17]. In accord, eliminating the
13 tumors with deletions had little effect on the association (Table 5).
The contribution of MGMT to alkylator resistance is also evidenced by
the signiﬁcantly longer PFS accompanying less than median MGMT
activity for all diagnoses (Table 6).
As indicated in Table 4, withholding alkylator treatment until
progression following RT was associated with a greater risk of progres-
sion and signiﬁcantly shorter PFS (16 vs. 26months; P≤ 0.014). Howev-
er, MGMT was signiﬁcantly inversely associated with PFS in both
dichotomous and continuous regression models regardless of inter-
vening progression after RT (Table 5). The relationship ofMGMTactivity
with PFS was also comparable between AGs that had progressed from
low-grade glioma and those that had not, suggesting that malignant
progression did not affect the contribution of MGMT to resistance. As
gliomas are graded to the most malignant histology observed, our
ﬁndings also suggest that the presence of low-grade tumor cells in
AGs does not affect the role of MGMT in determining response to
alkylators. Finally, analysis of groups by alkylator regimen revealed
signiﬁcant inverse associations in dichotomous and continuous models
between MGMT activity and PFS for the 42 tumors receiving PCV, the
most frequent treatment regimen, as well as signiﬁcant associations
for the 42 tumors treated with other alkylating agents (Table 5). In all
cases, these associations were reﬂected in the longer PFS for tumors
with less than median MGMT activity (Table 6). Importantly, MGMT
activity showed no relationship with PFS in AGs treated solely with
RT, andwith overall survival in AGs treated with both RT and alkylators
(Tables 5 and 6). These ﬁndings strongly suggest that that the associa-
tion between MGMT and PFS reﬂects the repair of O6-alkylguanine ad-
ducts, and that the contribution of MGMT to alkylator resistance is
independent of prognostic markers associated with therapeutic
response.
3.7. MGMT activity and CpG methylation status
As noted earlier, CpGmethylation of theMGMT promoter is associat-
ed with better outcome following alkylator therapy in GBMs, and
methylation has been associated in some, but not all, studies, with low
or absent MGMT activity [22,23]. Here, we analyzed the relationship
of MGMT activitywithMGMT promotermethylation status, determined
by MSP [30,31], in 47 of the GBMs described above for which sufﬁcient
DNA was available. This subgroup is similar to the larger sample from
which it was drawn in MGMT activity (11 ± 10 vs. 9.4 ± 11 fmol/106
cells) and comparable in PFS (5.5 vs. 6months). In the 47 GBMs, greater
than median MGMT activity was accompanied by greater risk of
progression (HR = 1.98; P ≤ 0.04) and shorter PFS (5 vs. 6.5 months;
P≤ 0.03). Twenty-seven percent (12/45) of GBMsdisplayedmethylated
promoters; these tumors had a lower risk of progression (HR = 0.297;
P ≤ 0.009) and longer PFS than the unmethylated tumors (7.5 vs. 5
months; P ≤ 0.002), in accord with previous observations [3]. Impor-
tantly, Fig. 2 shows that promoter methylation was accompanied by
signiﬁcantly lower mean MGMT activity (4.7 ± 2.6 vs. 14 ± 11 fmol/
106 cells; P≤ 0.001), suggesting that the longer PFS following alkylator
therapy of methylated GBMs is associated with lower capacity to
remove cytotoxic O6-alkylguanine adducts.
Fig. 2 also shows that the activities of 56% (19/34) of the
unmethylated GBMs fell within the range observed for methylated
tumors. As illustrated in Fig. 3A, PFS for these unmethylated tumors
with low MGMT activity remained signiﬁcantly shorter than that formethylated tumors (5 vs. 7.5 months; P ≤ 0.005). This ﬁnding suggests
that low MGMT activity alone is not sufﬁcient to account for the
difference in survival between unmethylated and methylated tumors.
As shown in Fig. 3B, further analysis restricted to the 34 unmethylated
GBMs revealed that tumors with greater than median MGMT activity
(10 fmol/106 cells for this sample) had shorter PFS (4 vs. 6.5 months;
P ≤ 0.015) and a signiﬁcantly higher risk for progression than tumors
with less than median activity in a univariate model (HR = 2.45; P ≤
0.030). This ﬁnding suggests that among unmethylated GBMs lower
MGMT activity is accompanied by greater sensitivity to alkylators. The
small number of methylated GBMs precluded comparable analysis.
We also determined promoter methylation status in 34 of the AGs
for which sufﬁcient DNA was available. These tumors were comparable
to the larger group from which they were drawn in MGMT activity
(6.6 ± 6.7 vs. 5.9 ± 7.0 fmol/106 cells), and PFS (26 vs. 17 months)
and proportion of diagnoses. This subgroup was also comparable in
that greater than median MGMT activity was accompanied by signiﬁ-
cantly higher risk of progression (HR = 2.81; P ≤ 0.02) and shorter
PFS (8 vs. 48 months; P ≤ 0.015). Promoter methylation was displayed
by 59% (20/34) of AGs and was accompanied by signiﬁcantly lower
risk for progression (HR = 0.113; P ≤ 0.001) and longer PFS (56 vs. 8
months; P ≤ 0.001). As illustrated in Fig. 2, mean MGMT activity was
2.3-fold lower in methylated tumors (3.7 ± 2.7 vs. 11 ± 8.6 fmol/106
cells; P ≤ 0.0001). Fig. 2 also shows that 64% (9/14) of unmethylated
AGs had MGMT activity that fell within the range observed for methyl-
ated tumors. However, low activity in these unmethylated tumors was
not accompanied by the longer PFS observed for methylated AGs
(12 vs. 56 months; P ≤ 0.001; Fig. 3C), suggesting that mechanisms in
addition to MGMT are responsible for the better response to alkylators
in methylated AGs.4. Discussion
The role of MGMT in the response of GBM and other gliomas to
treatment has been the focus of intensive investigation by the inter-
national neuro-oncology community during the last decade [2–4]. The
association of improved response to chemo-RT with MGMT promoter
Fig. 3. Comparison of survival ofMGMT promoter methylated and unmethylated GBM (A) and AG (C) with overlappingMGMT activities and of (B) promoter unmethylated GBM dichot-
omized by MGMT activity. Survival was calculated by the method of Kaplan–Meier. As illustrated in A and C, unmethylated GBMs and AGs had signiﬁcantly shorter PFS despite having
MGMT activity comparable to that of methylated tumors (6.3 ± 3.6 vs. 4.4 ± 3.76 fmol/106 cells for GBMs and 5.9 ± 3.4 vs. 3.8 ± 2.7 fmol/106 cells for AGs). Panel B illustrates the
signiﬁcantly shorter PFS of unmethylated GBM expressing greater than median MGMT activity (10 fmol/106 cells).
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suggests that impaired ability to remove cytotoxic O6-meG and other
O6-alkylguanine adducts imparts better outcome following alkylator-
based therapies. However, whether the better clinical outcome
primarily reﬂects removal of cytotoxic O6-alkylguanine adducts
remains to be conﬁrmed, as previous studies have failed to consistently
show that tumor MGMT expression or activity is inversely correlated
with glioma response to alkylating agent-based therapies [9,18,19].
Elucidation of the underlying mechanism is critical if MGMT is to
be used to direct treatment decisions and to serve as a target for anti-
resistance therapies. Here we present evidence that lowMGMT activity
is associated with better response to alkylating agent therapy and with
promoter methylation in high-grade gliomas.
A primary goal of our study was to examine the relationship of
MGMT activity with PFS following alkylator-based therapy in 91
GBMs, themost frequently diagnosed glioma.We found a strong inverse
association between PFS and activity following alkylating agent treat-
ment in Cox regression models (Table 2). In the dichotomous model,
GBMs with greater than median MGMT activity were more than twice
as likely to progress relative to tumors with lower activity, resulting in
a signiﬁcantly shortened PFS (Fig. 1; Table 3). These observations are
in accordwith an earlier report that highMGMT activity is accompanied
by signiﬁcantly shorter PFS in 24 GBMs treated concomitantly with
radiation and either TMZ or chloroethylating agents [22]. Of note,
an analysis of MGMT expression by IHC in 418 GBMs found results
comparable to ours for tumors harboring greater than the median
fraction (30%) of immunopositive cells [19]. We also observed a signiﬁ-
cant inverse association between MGMT activity and PFS in continuous
Cox regression models (Table 2), which revealed that GBMs with the
highest and lowest activities differed in risk of progression by more
than 5- to 7-fold. To our knowledge, this is the ﬁrst examination of the
association of MGMT activity with alkylator response in a continuous
model that allows the evaluation of the relative risk of progression
among individual GBMs rather than between two tumor cohorts.
We used PFS after initiating alkylator therapy as an endpoint in
our analyses to provide evidence that the association between activity
and clinical outcome is a reﬂection of MGMT-mediated removal of
potentially lethal O6-alkylguanine lesions. This premise is supported
by the lack of correlation of MGMT activity with PFS in GBM treated
with RT alone or with overall survival (Table 2). Further evidence is
provided by the independence of the relationship on prior clinical
course and on the alkylator chemotherapy employed (Table 2). These
observations suggest a causal relationship that is speciﬁc to alkylation
and that low MGMT activity is not simply a non-speciﬁc marker for
GBMs that are inherently more susceptible to any therapeutic interven-
tion. The persistence of the relationship in smaller sub-groups of GBMs
indicates that the association of activity with clinical response does not
reﬂect the inﬂuence of a small number of unrepresentative samples, a
conclusion validated by analysis of groups that either excluded
specimens with outlier MGMT or extreme values for PFS (Table 2).These considerations, together with the reduced risk of progression
that accompanies low activity, support the development of clinically
tractable methods to inhibit MGMT expression in order to suppress
resistance to alkylating agents in GBM and improve therapeutic
outcome.
In accord with our results for GBM, we found that MGMT activity is
inversely associated with response to alkylating agent therapy in AGs,
regardless of diagnosis and clinical course, in both dichotomous and
continuous regression models (Table 5). Notably, anaplastic tumors
have appreciably lower mean MGMT activity than GBM (5.9 ± 7.0 vs.
10 ± 11 fmol/106 cells; P ≤ 0.004), suggesting that the longer post-
alkylator PFS observed for AGs (17 vs. 6 months; P ≤ 0.001), reﬂects,
at least in part, a greater dependence on MGMT for resistance. This
conclusion is supported by the signiﬁcant difference in HR between
newly operated AGs and GBMs (HR = 1.124; CI [1.071; 1.180] vs.
HR = 1.033 CI [1.012; 1.054]; note non-overlapping CIs). This
difference in risk persists when analysis excludes AGs known to harbor
1p and/or 19q deletions (HR= 1.117; CI [1.061; 1.175]), suggesting the
greater risk does not reﬂect the presence of treatment hypersensitive
deleted tumors. While the difference in alkylator sensitivity likely
involves a multiplicity of intrinsic factors, AGs may not be as proﬁ-
cient in dealing with the cytotoxic consequences of unrepaired
O6 = alkylguanine (e.g., replication fork collapse; double-strand break
formation [11,33]), thus increasing the vulnerability of tumors with
lowMGMT activity.While it is difﬁcult to deﬁnitively assign signiﬁcance
to these ﬁndings because of the small cohort size and the divergent
clinical behavior for each AG diagnosis, they do suggest that suppres-
sion of MGMT activity in AGsmay be as or more effective than in GBMs.
We also found that the reduced risk of progression in GBMs and
AGs displaying MGMT promoter methylation was accompanied by
lower MGMT activity (Fig. 2). Our ﬁndings are in accord with those
of others [13] as well as the recent report that the fraction of cells
immunopositive for MGMT is signiﬁcantly lower in methylated GBMs
[19]. These results support the hypothesis that the better treatment
outcome associated with promoter methylation is due, at least in part,
to decreased removal of O6-alkylguanine adducts. However, we found
that the range of MGMT activities overlapped appreciably between
methylated and unmethylated GBMs and AGs. Such overlap has been
reported previously for both MGMT activity [22] and MGMT protein
expression [19] in GBMs. Detectable activity in methylated GBMs
may in part reﬂect the presence of contaminating normal cells that
express MGMT. However, emerging data strongly indicate that MGMT
expression in GBMs is directly correlated with the number of methylat-
ed CpG dinucleotides in the MGMT promoter [13,19], a feature not
evaluated by the MSP assay. Thus, tumor cells harboring incompletely
methylated promoters may contribute to the activity in GBMs judged
to be methylated by MSP. The overlap of activities may also reﬂect
induction of MGMT expression in methylated tumors in response to
exposure to corticosteroids, as suggested by work of Weiler et al. [4].
In accord with this hypothesis, Weiler et al. found that PFS was reduced
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concomitant treatment with corticosteroids and alkylators compared
to treatment with alkylators alone. Nevertheless, we found that the
prolonged PFS that accompanies low MGMT activity in methylated
gliomas was not observed in unmethylated tumors with comparable
activity (Fig. 3 A & C). This novel ﬁnding suggests thatMGMT promoter
methylation is associated with an alkylation sensitive phenotype that is
absent in unmethylated gliomas with low MGMT activity. While the
identity of the genes critical for clinical response remains to be
completely elucidated, promoter CpG island methylation appears to
silence the expression of a number of DNA repair activities in addition
toMGMT, suggesting possible candidate genes that inﬂuence sensitivity
to alkylating agent-based treatment [34]. These include components of
base excision repair that excise cytotoxic N-alkylpurines and abasic sites
[10,19], and of post-replication repair pathways that either prevent or
repair the double-strand breaks that can arise when DNA replication
forks encounter unrepaired O6-alkylguanine adducts [33,35]. Suppres-
sion of these repair activities has been shown to enhance alkylator
sensitivity in human glioma cell lines [10,28,36,37]. Demonstration of
concomitant suppression ofMGMT and one ormore of theseDNA repair
activities accompanying better response to therapy would further
elucidate the mechanism(s) responsible for alkylation hypersensitivity
accompanyingMGMT promoter methylation in malignant gliomas and
identify new targets for anti-resistance therapies.
A second novel ﬁnding of our study is that the inverse association
between MGMT activity and PFS persists in unmethylated GBMs
(Fig. 3B). This result demonstrates the relationship between MGMT
activity and PFS in the presence of resistance mechanisms that counter
the cytotoxicity of unrepaired O6-meG in unmethylated GBMs that are
absent or reduced in methylated tumors. This ﬁnding also suggests
that MGMT activity may be used to stratify risk of progression within
groups of unmethylated and methylated tumors as has been proposed
forMGMTprotein expression evaluated by IHC [19].While thehigh sen-
sitivity of biochemical assay and the wide range of activities displayed
by GBMs and AGs (~300-fold) support the use of MGMT activity to
further stratify risk of progression, the nature of the biochemical assay,
requiring extract preparation from intact tissue and the use of a radioac-
tive substrate that is not commercially available, make it unsuitable for
routine clinical use. Nonetheless, our results suggest that biochemical
assay has an important role in characterizing the contribution of
MGMT to resistance to alkylating agent treatment and in corroborating
promoter methylation assays.
5. Conclusions
The biochemical activity of MGMT is inversely associated with PFS
following alkylating-agent based chemotherapy in GBM and AGs. The
relationship is speciﬁc to alkylating agents and is independent of clinical
course and alkylator regimen indicating that the association reﬂects the
removal of O6-alkylguanine adducts. Signiﬁcantly lowermean activity is
positively correlated with MGMT promoter CpG methylation despite
considerable overlap of activity betweenmethylated and unmethylated
tumors. The shorter PFS displayed by unmethylated tumors with
overlapping activity suggests that resistance mechanisms in addition
toMGMT are suppressed inmethylated tumors. Our ﬁndings emphasize
the need to develop strategies to inhibit MGMT activity in order to
improve clinical outcome in malignant gliomas.
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